PTC THERAPEUTICS INC (PTCT)

US69366J2006 - Common Stock

27.95  +0.88 (+3.25%)

After market: 27.95 0 (0%)

Fundamental Rating

1

Overall PTCT gets a fundamental rating of 1 out of 10. We evaluated PTCT against 597 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. PTCT is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year PTCT has reported negative net income.
PTCT had a negative operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PTCT has a Return On Assets of -50.94%. This is comparable to the rest of the industry: PTCT outperforms 48.14% of its industry peers.
Industry RankSector Rank
ROA -50.94%
ROE N/A
ROIC N/A
ROA(3y)-26.55%
ROA(5y)-21.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PTCT's Gross Margin of 94.07% is amongst the best of the industry. PTCT outperforms 94.92% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PTCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.85%
GM growth 5Y-0.84%

1

2. Health

2.1 Basic Checks

PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTCT has more shares outstanding
PTCT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.

2.2 Solvency

PTCT has an Altman-Z score of -3.17. This is a bad value and indicates that PTCT is not financially healthy and even has some risk of bankruptcy.
PTCT has a Altman-Z score of -3.17. This is comparable to the rest of the industry: PTCT outperforms 40.85% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.17
ROIC/WACCN/A
WACC9.2%

2.3 Liquidity

PTCT has a Current Ratio of 1.10. This is a normal value and indicates that PTCT is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.10, PTCT is not doing good in the industry: 88.98% of the companies in the same industry are doing better.
A Quick Ratio of 1.03 indicates that PTCT should not have too much problems paying its short term obligations.
PTCT's Quick ratio of 1.03 is on the low side compared to the rest of the industry. PTCT is outperformed by 88.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 1.03

4

3. Growth

3.1 Past

PTCT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.64%.
Looking at the last year, PTCT shows a quite strong growth in Revenue. The Revenue has grown by 14.60% in the last year.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 29.16% on average per year.
EPS 1Y (TTM)-9.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-15.03%
Revenue 1Y (TTM)14.6%
Revenue growth 3Y31.54%
Revenue growth 5Y29.16%
Revenue growth Q2Q-9.44%

3.2 Future

The Earnings Per Share is expected to grow by 10.49% on average over the next years. This is quite good.
Based on estimates for the next years, PTCT will show a small growth in Revenue. The Revenue will grow by 2.95% on average per year.
EPS Next Y18.41%
EPS Next 2Y10.56%
EPS Next 3Y11.58%
EPS Next 5Y10.49%
Revenue Next Year31.73%
Revenue Next 2Y-6.49%
Revenue Next 3Y-5.01%
Revenue Next 5Y2.95%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

PTCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.56%
EPS Next 3Y11.58%

0

5. Dividend

5.1 Amount

No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield N/A

PTC THERAPEUTICS INC

NASDAQ:PTCT (2/26/2024, 7:00:01 PM)

After market: 27.95 0 (0%)

27.95

+0.88 (+3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.11B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.94%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 94.07%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.1
Quick Ratio 1.03
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-9.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y18.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.6%
Revenue growth 3Y31.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y